Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

Completed

• Conditions: Neuroendocrine Tumors

• Registration Number: NCT05013957
• Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary

Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach.

The aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand, existing tumor samples from the biobank of Basel University Hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-17
• Study First Submitted QC: 2021-08-17
• Study First Posted: 2021-08-20
• Study Start: 2022-01-01
• Status Verified: 2024-12
• Primary Completion: 2024-12-30
• Study Completion: 2024-12-30
• Last Update Submitted: 2025-01-27
• Last Update Posted: 2025-01-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• neuroendocrine tumor

Exclusion Criteria

• insufficient amount or quality of neuroendocrine tumor sample

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Methylation-based classification of NEN samples	3 years	NEN samples will be classified according to methylation analysis

Trial Locations

Locations (1)

University Hospital Basel, Department of Endocrinology; 🇨🇭 Basel, Basel Stadt, Switzerland